This page lists 299 expected clinical trial readouts covering June 2026 to December 2027. These dates come from company guidance and ClinicalTrials.gov, so most are known only to a month or a quarter, and we publish them at that precision rather than guessing a day.
These 59 dates are not trial-registry estimates. Each one is timing the company itself stated in an SEC filing, and each row links to that filing so you can read the sentence it came from. Dates are shown at the precision the company used: a quarter stays a quarter rather than being rendered as a specific day it never named. Guidance that was vaguer than a quarter is not on this page at all.
| Guided | Ticker | Program | Company | Source |
|---|---|---|---|---|
| Aug 2026 | ALZN | AL001 | Alzamend Neuro, Inc. | 10-K 2026-07-22 |
| Aug 2026 | MPLT | ML-007C | MapLight Therapeutics, Inc. | EX-99.1 2026-05-14 |
| Aug 2026 | TENX | LEVEL-2 | TENAX THERAPEUTICS, INC. | 10-Q 2026-07-31 |
| Aug 2026 | TYRA | SURF303 | Tyra Biosciences, Inc. | EX-99.1 2026-05-13 |
| Q3 2026 | AARD | ARD-101 | Aardvark Therapeutics, Inc. | EX-99.2 2026-02-12 |
| Q3 2026 | ABCL | ABCL635 | AbCellera Biologics Inc. | EX-99.2 2026-05-11 |
| Q3 2026 | ALMS | anifrolumab | ALUMIS INC. | EX-99.1 2026-06-29 |
| Q3 2026 | BOLT | BDC-4182 | Bolt Biotherapeutics, Inc. | EX-99.1 2026-03-12 |
| Q3 2026 | DFTX | DT120 | Definium Therapeutics, Inc. | 424B5 2026-06-24 |
| Q3 2026 | EVMN | EVO756 | Evommune, Inc. | EX-99.1 2026-06-29 |
| Q3 2026 | GPCR | ACCG-2671 | Structure Therapeutics Inc. | EX-99.1 2026-05-07 |
| Q3 2026 | IMMX | NXC-201 | Immix Biopharma, Inc. | 8-K 2026-03-30 |
| Q3 2026 | IRON | DISC-3405 | Disc Medicine, Inc. | EX-99.1 2026-07-30 |
| Q3 2026 | KOD | KSI-501 | Kodiak Sciences Inc. | EX-99.1 2026-05-07 |
| Sep 2026 | MBRX | Annamycin | Moleculin Biotech, Inc. | EX-99.1 2026-07-31 |
| Q3 2026 | MNKD | MNKD-201 | MANNKIND CORP | EX-99.1 2026-05-06 |
| Q3 2026 | OCGN | OCU400 | Ocugen, Inc. | EX-99.1 2026-05-04 |
| Q3 2026 | PHVS | deucrictibant | Pharvaris N.V. | EX-99.1 2026-06-11 |
| Q3 2026 | PMN | PMN310 | ProMIS Neurosciences Inc. | EX-99.1 2026-05-12 |
| Q3 2026 | PPBT | IM1305 | PURPLE BIOTECH LTD. | EX-99.1 2026-03-19 |
| Sep 2026 | ROIV | brepocitinib | Roivant Sciences Ltd. | 10-K 2026-05-20 |
| Q3 2026 | SCYX | SCY-247 | SCYNEXIS INC | EX-10.1 2026-05-11 |
| Q3 2026 | STTK | SL-846 | Shattuck Labs, Inc. | EX-99.3 2026-06-09 |
| Q3 2026 | SYRE | SPY001 | Spyre Therapeutics, Inc. | EX-99.1 2026-05-05 |
| Q3 2026 | TECX | TX2100 | Tectonic Therapeutic, Inc. | EX-99.1 2026-05-07 |
| Q3 2026 | VKTX | VK2735 | Viking Therapeutics, Inc. | n/a |
| Q3 2026 | VTGN | fasedienol | Vistagen Therapeutics, Inc. | EX-99.1 2026-06-15 |
| Q3 2026 | WHWK | HWK-007 | Whitehawk Therapeutics, Inc. | EX-99.1 2026-05-07 |
| Q3 2026 | XENE | XEN1701 | Xenon Pharmaceuticals Inc. | EX-99.1 2026-05-07 |
| Q4 2026 | ALNY | elebsiran | ALNYLAM PHARMACEUTICALS, INC. | 10-K 2026-02-12 |
| Q4 2026 | ATAI | VLS-01 | AtaiBeckley Inc. | EX-99.1 2026-05-12 |
| Q4 2026 | BMEA | BMF-650 | Biomea Fusion, Inc. | EX-99.1 2026-05-11 |
| Q4 2026 | CMPX | CTX-10726 | Compass Therapeutics, Inc. | EX-99.1 2026-05-05 |
| Dec 2026 | CRIS | NCT07271667 | CURIS INC | 10-Q 2026-05-13 |
| Q4 2026 | ENTA | EDP-978 | ENANTA PHARMACEUTICALS INC | 424B5 2026-07-02 |
| Q4 2026 | HELP | HLP003 | CYBIN INC. | EX-99.1 2026-08-03 |
| Q4 2026 | IPSC | CNTY-813 | Century Therapeutics, Inc. | EX-99.1 2026-06-08 |
| Q4 2026 | KYNB | FG-3246 | KYNTRA BIO, INC. | 10-Q 2026-05-12 |
| Q4 2026 | LONA | ATH-1105 | LeonaBio, Inc. | EX-99.1 2026-05-07 |
| Q4 2026 | MIRM | AZURE-1 | Mirum Pharmaceuticals, Inc. | EX-99.1 2026-05-06 |
| Q4 2026 | MTVA | DA-1726 | MetaVia Inc. | EX-99.1 2026-04-10 |
| Q4 2026 | PCVX | OPUS-1 | Vaxcyte, Inc. | EX-99.1 2026-05-06 |
| Q4 2026 | RAPP | RAP-219 | Rapport Therapeutics, Inc. | EX-99.1 2026-05-07 |
| Q4 2026 | RGNX | RGX-314 | REGENXBIO Inc. | EX-99.1 2026-06-29 |
| Q4 2026 | SKYE | nimacimab | Skye Bioscience, Inc. | 10-Q 2026-05-11 |
| Q4 2026 | SLGL | SGT-610 | Sol-Gel Technologies Ltd. | EX-99.1 2026-05-28 |
| Q4 2026 | SLS | SLS009 | SELLAS Life Sciences Group, Inc. | EX-99.1 2026-05-12 |
| Q4 2026 | SLS | galinpepimut-S (GPS) event-driven | SELLAS Life Sciences Group, Inc. | n/a |
| Q4 2026 | SNDX | SNDX-62122 | Syndax Pharmaceuticals Inc | EX-99.1 2026-07-14 |
| Q4 2026 | TRAX | ANB033 | First Tracks Biotherapeutics, Inc. | EX-99.1 2026-05-14 |
| Q4 2026 | TTRX | GX-03 | Turn Therapeutics Inc. | EX-99.1 2026-07-28 |
| Q4 2026 | ZBIO | ZB021 | Zenas BioPharma, Inc. | EX-99.1 2026-05-13 |
| Q1 2027 | AKTS | AKY-1189 | Aktis Oncology, Inc. | EX-99.1 2026-05-11 |
| Q1 2027 | CRBP | CRB-701 | Corbus Pharmaceuticals Holdings, Inc. | 10-Q 2026-05-12 |
| Q1 2027 | NMRA | NMRA-511 | Neumora Therapeutics, Inc. | EX-99.1 2026-05-07 |
| Q1 2027 | OCUL | HELIOS-3 | OCULAR THERAPEUTIX, INC | 10-Q 2026-05-05 |
| Q1 2027 | QNCX | LAM-001 | Quince Therapeutics, Inc. | EX-99.4 2026-07-30 |
| Q2 2027 | PROK | REGEN-006 | PROKIDNEY CORP. | EX-99.2 2026-05-15 |
| Q4 2027 | KLRS | TH103 | Kalaris Therapeutics, Inc. | EX-99.2 2026-07-17 |